Literature DB >> 27335385

Live Attenuated Borrelia burgdorferi Targeted Mutants in an Infectious Strain Background Protect Mice from Challenge Infection.

Beth L Hahn1, Lavinia J Padmore1, Laura C Ristow2, Michael W Curtis2, Jenifer Coburn3.   

Abstract

Borrelia burgdorferi, B. garinii, and B. afzelii are all agents of Lyme disease in different geographic locations. If left untreated, Lyme disease can cause significant and long-term morbidity, which may continue after appropriate antibiotic therapy has been administered and live bacteria are no longer detectable. The increasing incidence and geographic spread of Lyme disease are renewing interest in the vaccination of at-risk populations. We took the approach of vaccinating mice with two targeted mutant strains of B. burgdorferi that, unlike the parental strain, are avirulent in mice. Mice vaccinated with both strains were protected against a challenge with the parental strain and a heterologous B. burgdorferi strain by either needle inoculation or tick bite. In ticks, the homologous strain was eliminated but the heterologous strain was not, suggesting that the vaccines generated a response to antigens that are produced by the bacteria both early in mammalian infection and in the tick. Partial protection against B. garinii infection was also conferred. Protection was antibody mediated, and reactivity to a variety of proteins was observed. These experiments suggest that live attenuated B. burgdorferi strains may be informative regarding the identification of protective antigens produced by the bacteria and recognized by the mouse immune system in vivo Further work may illuminate new candidates that are effective and safe for the development of Lyme disease vaccines.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27335385      PMCID: PMC4979176          DOI: 10.1128/CVI.00302-16

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  50 in total

Review 1.  The Lyme disease vaccine--a public health perspective.

Authors:  Angela K Shen; Paul S Mead; Charles B Beard
Journal:  Clin Infect Dis       Date:  2011-02       Impact factor: 9.079

2.  Characterization of a candidate Borrelia burgdorferi beta3-chain integrin ligand identified using a phage display library.

Authors:  J Coburn; W Chege; L Magoun; S C Bodary; J M Leong
Journal:  Mol Microbiol       Date:  1999-12       Impact factor: 3.501

3.  A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato.

Authors:  Nina Wressnigg; P Noel Barrett; Eva-Maria Pöllabauer; Maria O'Rourke; Daniel Portsmouth; Michael G Schwendinger; Brian A Crowe; Ian Livey; Thomas Dvorak; Bernhard Schmitt; Markus Zeitlinger; Herwig Kollaritsch; Meral Esen; Peter G Kremsner; Tomas Jelinek; Roland Aschoff; Roland Weisser; Ingomar F K Naudts; Gerald Aichinger
Journal:  Clin Vaccine Immunol       Date:  2014-09-03

4.  Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB, and the saponin adjuvant QS21.

Authors:  R T Coughlin; D Fish; T N Mather; J Ma; C Pavia; P Bulger
Journal:  J Infect Dis       Date:  1995-04       Impact factor: 5.226

5.  Targeted mutation of the outer membrane protein P66 disrupts attachment of the Lyme disease agent, Borrelia burgdorferi, to integrin alphavbeta3.

Authors:  Jenifer Coburn; Carla Cugini
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-14       Impact factor: 11.205

6.  Immunological and molecular polymorphisms of OspC, an immunodominant major outer surface protein of Borrelia burgdorferi.

Authors:  B Wilske; V Preac-Mursic; S Jauris; A Hofmann; I Pradel; E Soutschek; E Schwab; G Will; G Wanner
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

7.  Searching for borrelial T cell epitopes associated with antibiotic-refractory Lyme arthritis.

Authors:  Elise E Drouin; Lisa Glickstein; William W Kwok; Gerald T Nepom; Allen C Steere
Journal:  Mol Immunol       Date:  2008-01-11       Impact factor: 4.407

8.  Isolation and cultivation of Lyme disease spirochetes.

Authors:  A G Barbour
Journal:  Yale J Biol Med       Date:  1984 Jul-Aug

9.  Notes from the field: update on Lyme carditis, groups at high risk, and frequency of associated sudden cardiac death--United States.

Authors:  Joseph D Forrester; Jonathan Meiman; Jocelyn Mullins; Randall Nelson; Starr-Hope Ertel; Matt Cartter; Catherine M Brown; Virginia Lijewski; Elizabeth Schiffman; David Neitzel; Elizabeth R Daly; Abigail A Mathewson; Whitney Howe; Lindsay A Lowe; Natalie R Kratz; Shereen Semple; P Bryon Backenson; Jennifer L White; Phillip M Kurpiel; Russell Rockwell; Kirsten Waller; Diep Hoang Johnson; Christopher Steward; Brigid Batten; Dianna Blau; Marlene DeLeon-Carnes; Clifton Drew; Atis Muehlenbachs; Jana Ritter; Jeanine Sanders; Sherif R Zaki; Claudia Molins; Martin Schriefer; Anna Perea; Kiersten Kugeler; Christina Nelson; Alison Hinckley; Paul Mead
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-10-31       Impact factor: 17.586

10.  Essential role for OspA/B in the life cycle of the Lyme disease spirochete.

Authors:  Xiaofeng F Yang; Utpal Pal; Sophie M Alani; Erol Fikrig; Michael V Norgard
Journal:  J Exp Med       Date:  2004-02-23       Impact factor: 14.307

View more
  5 in total

1.  The Factor H-Binding Site of CspZ as a Protective Target against Multistrain, Tick-Transmitted Lyme Disease.

Authors:  Ashley L Marcinkiewicz; Yi-Pin Lin; Ilva Lieknina; Xiuli Yang; Patricia L Lederman; Thomas M Hart; Jennifer Yates; Wen-Hsiang Chen; Maria Elena Bottazzi; Nicholas J Mantis; Peter Kraiczy; Utpal Pal; Kaspars Tars
Journal:  Infect Immun       Date:  2020-04-20       Impact factor: 3.441

2.  Eliminating Factor H-Binding Activity of Borrelia burgdorferi CspZ Combined with Virus-Like Particle Conjugation Enhances Its Efficacy as a Lyme Disease Vaccine.

Authors:  Ashley L Marcinkiewicz; Ilva Lieknina; Svetlana Kotelovica; Xiuli Yang; Peter Kraiczy; Utpal Pal; Yi-Pin Lin; Kaspars Tars
Journal:  Front Immunol       Date:  2018-02-08       Impact factor: 7.561

3.  Structural and Biomolecular Analyses of Borrelia burgdorferi BmpD Reveal a Substrate-Binding Protein of an ABC-Type Nucleoside Transporter Family.

Authors:  Gabriela Guédez; Tiina A Salminen; Jukka Hytönen; Julia Cuellar; Mia Åstrand; Heli Elovaara; Annukka Pietikäinen; Saija Sirén; Arto Liljeblad
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

4.  A live attenuated-vaccine model confers cross-protective immunity against different species of the Leptospira genus.

Authors:  Elsio A Wunder; Haritha Adhikarla; Camila Hamond; Katharine A Owers Bonner; Li Liang; Camila B Rodrigues; Vimla Bisht; Jarlath E Nally; David P Alt; Mitermayer G Reis; Peter J Diggle; Philip L Felgner; Albert Ko
Journal:  Elife       Date:  2021-01-26       Impact factor: 8.140

5.  Protective Immunity and New Vaccines for Lyme Disease.

Authors:  Maria Gomes-Solecki; Paul M Arnaboldi; P Bryon Backenson; Jorge L Benach; Christopher L Cooper; Raymond J Dattwyler; Maria Diuk-Wasser; Erol Fikrig; J W Hovius; Will Laegreid; Urban Lundberg; Richard T Marconi; Adriana R Marques; Philip Molloy; Sukanya Narasimhan; Utpal Pal; Joao H F Pedra; Stanley Plotkin; Daniel L Rock; Patricia Rosa; Sam R Telford; Jean Tsao; X Frank Yang; Steven E Schutzer
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.